Company Overview
About Alamar Biosciences
Alamar Biosciences is a Fremont, California-based life sciences company founded in 2020 with a focus on advancing proteomics through ultrasensitive biomarker detection technology. The company's flagship platform, NULISA (Nucleic acid-Linked Immuno-Sandwich Assay), enables researchers to simultaneously measure hundreds of protein biomarkers from very small sample volumes — including blood, cerebrospinal fluid, and other biological matrices — with sensitivity orders of magnitude beyond conventional assays like ELISA. This capability is critical for detecting disease-associated proteins at very early stages before symptoms manifest.
Business Model & Competitive Advantage
Alamar has raised over $140M in funding, including a $100M Series C round. The capital supports continued platform development, expansion of the NULISA panel library (covering neurodegeneration, oncology, cardiovascular, and inflammatory disease biomarkers), and commercialization into pharma, biotech, and academic research markets. The company's proximity to major Bay Area biotech clusters and its partnerships with leading academic medical centers accelerate adoption among translational researchers.
Competitive Landscape 2025–2026
The NULISA platform addresses a significant unmet need in precision medicine: most existing proteomic tools sacrifice either sensitivity or multiplex capability. NULISA achieves both — enabling low-abundance biomarker detection at scale. This positions Alamar competitively against established proteomics players like Olink (acquired by Thermo Fisher Scientific) and SomaScan (SomaLogic), while its high sensitivity profile makes it particularly relevant for neurodegenerative disease research (Alzheimer's, Parkinson's) where plasma biomarkers are present at extremely low concentrations.
Key Differentiators
Emerging Innovator
Alamar Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Compare Alamar Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alamar Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alamar Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alamar Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →